Skip to main content

Ezallor Disease Interactions

There are 5 disease interactions with Ezallor (rosuvastatin).

Major

HMG-CoA reductase inhibitors (applies to Ezallor) rhabdomyolysis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Myopathy, Myoneural Disorder, Hypothyroidism, Renal Dysfunction

Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors. The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal. Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect. Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain. HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.

References

  1. Schalke BB, Schmidt B, Toyka K, Hartung H-P (1992) "Pravastatin-associated inflammatory myopathy." N Engl J Med, 327, p. 649-50
  2. Pierce LR, Wysowski DK, Gross TP (1990) "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA, 264, p. 71-5
  3. Walker JF (1989) "Simvastatin: the clinical profile." Am J Med, 87, s44-6
  4. Simons LA (1993) "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol, 16, p. 317-22
  5. McGovern ME, Mellies MJ (1993) "Long-term experience with pravastatin in clinical research trials." Clin Ther, 15, p. 57-64
  6. Reaven P, Witztum JL (1988) "Lovastatin, nicotinic acid, and rhabdomyolysis." Ann Intern Med, 109, p. 597-8
  7. (1993) "Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med, 153, p. 1079-87
  8. Corpier CL, Jones PH, Suki WN, et al. (1988) "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA, 260, p. 239-41
  9. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA (1988) "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med, 318, p. 47-8
  10. Norman DJ, Illingworth DR, Munson J, Hosenpud J (1988) "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med, 318, p. 46-7
  11. Wallace CS, Mueller BA (1992) "Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs." Ann Pharmacother, 26, p. 190-2
  12. Bilheimer DW (1990) "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology, 77, p. 58-65
  13. (2002) "Product Information. Mevacor (lovastatin)." Merck & Co., Inc
  14. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  15. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  16. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK (1993) "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med, 94, p. 109-10
  17. McDonagh J, Winocour P, Walker DJ (1993) "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol, 32, p. 647-8
  18. Levy RI, Troendle AJ, Fattu JM (1993) "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation, 87, i45-53
  19. (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
  20. Fernandezzatarain G, Navarro V, Garcia H, Villatoro J, Calvo C (1994) "Rhabdomyolysis and acute renal failure associated with lovastatin." Nephron, 66, p. 483-4
  21. Jokubaitis LA (1994) "Updated clinical safety experience with fluvastatin." Am J Cardiol, 73, d18-24
  22. Lees RS, Lees AM (1995) "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med, 333, p. 664-5
  23. Ahmand S (1995) "Lovastatin-induced myopathy in a hypothyroid patient." J Fam Pract, 41, p. 227-8
  24. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso (1996) "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med, 156, p. 2085-92
  25. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM (1996) "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA, 275, p. 128-33
  26. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  27. Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ (1996) "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med, 240, p. 403-4
  28. (2001) "Product Information. Baycol (cerivastatin)." Bayer
  29. Grunden JW, Fisher KA (1997) "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother, 31, p. 859-63
  30. Iliadis EA, Rosenson RS (1999) "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol, 22, p. 25-8
  31. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ (1996) "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med, 240, p. 403-4
  32. Alvarez JM, Rawdanowiz TJ, Goldstein J (1998) "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg, 116, p. 654-5
  33. Pogson GW, Kindred LH, Carper BG (1999) "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol, 83, p. 1146
  34. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
  35. (2010) "Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)
View all 35 references
Moderate

HMG-CoA reductase inhibitors (applies to Ezallor) cognitive impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: CNS Disorder

Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins. The reports are usually not serious, and reversible upon statin discontinuation. Caution is recommended when using these agents in patients with cognitive impairment.

References

  1. (2002) "Product Information. Mevacor (lovastatin)." Merck & Co., Inc
  2. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  3. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  4. (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
  5. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  6. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
View all 6 references
Moderate

HMG-CoA reductase inhibitors (applies to Ezallor) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors. Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.

References

  1. (2002) "Product Information. Mevacor (lovastatin)." Merck & Co., Inc
  2. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  3. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  4. (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
  5. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  6. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
  7. (2010) "Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)
View all 7 references
Moderate

HMG-CoA reductase inhibitors (applies to Ezallor) renal disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease. Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients. Caution and close monitoring is advised when using these drugs in patients with renal impairment.

References

  1. (2002) "Product Information. Mevacor (lovastatin)." Merck & Co., Inc
  2. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  3. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  4. (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
  5. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  6. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
  7. (2010) "Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)
View all 7 references
Moderate

Rosuvastatin (applies to Ezallor) hematuria/proteinuria

Moderate Potential Hazard, Moderate plausibility.

An association between rosuvastatin and the development of proteinuria and microscopic hematuria was observed among treated patients during clinical trials. Patients with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing should be instructed to reduce the dose of rosuvastatin according to clinical standards. Therapy with rosuvastatin should be administered cautiously in patients showing abnormal urinalysis. Monitoring for proteinuria and hematuria is recommended.

References

  1. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc

Ezallor drug interactions

There are 226 drug interactions with Ezallor (rosuvastatin).

Ezallor alcohol/food interactions

There is 1 alcohol/food interaction with Ezallor (rosuvastatin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer